Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $153.3 million.

  • Heron Therapeutics' Shares Outstanding (Weighted Average) rose 1.07% to $153.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.3 million, marking a year-over-year increase of 1.07%. This contributed to the annual value of $152.1 million for FY2024, which is 1.35% up from last year.
  • As of Q3 2025, Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $153.3 million, which was up 0.48% from $152.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Shares Outstanding (Weighted Average) registered a high of $153.3 million during Q3 2025, and its lowest value of $91.4 million during Q1 2021.
  • For the 3-year period, Heron Therapeutics' Shares Outstanding (Weighted Average) averaged around $144.8 million, with its median value being $150.7 million (2024).
  • Data for Heron Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 37.15% (in 2023) over the last 5 years.
  • Over the past 5 years, Heron Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $101.9 million in 2021, then rose by 16.63% to $118.9 million in 2022, then climbed by 26.23% to $150.1 million in 2023, then grew by 1.35% to $152.1 million in 2024, then rose by 1.07% to $153.3 million in 2025.
  • Its last three reported values are $153.3 million in Q3 2025, $152.6 million for Q2 2025, and $152.3 million during Q1 2025.